MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer

(University of Texas M. D. Anderson Cancer Center) MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news